The global rigid endoscopes market size was estimated at USD 7.31 billion in 2024 and is projected to reach USD 11.11 billion by 2033, growing at a CAGR of 4.74% from 2025 to 2033. This steady market growth is primarily driven by the increasing global prevalence of cancer and the rising rate of cancer-related mortality, which continue to place a significant burden on healthcare systems worldwide. As cancer incidence increases, the demand for accurate, reliable, and minimally invasive diagnostic and therapeutic tools has grown substantially, supporting the expansion of the rigid endoscopes market.

For instance, according to the Cancer Progress Report 2023 released by the American Cancer Society, around 1,958,310 new cancer cases were diagnosed in the U.S. in 2023, while 609,820 individuals succumbed to the disease during the same year. Furthermore, projections suggest that by 2040, the number of new cancer cases in the U.S. alone could reach 2.3 million. These figures highlight the escalating burden of cancer and underscore the urgent need for early diagnosis and effective treatment strategies.

The rising prevalence of cancer and associated mortality rates globally is expected to remain a key factor driving market growth. As cancer cases continue to increase, healthcare providers are increasingly relying on advanced medical technologies to improve diagnostic accuracy and treatment outcomes. Rigid endoscopes play a critical role in this context, as they enable minimally invasive procedures that allow physicians to accurately diagnose, stage, and treat various types of cancer. Their ability to provide clear visualization, reduce patient recovery time, and minimize surgical trauma makes rigid endoscopes an essential tool in modern oncology and surgical practices.

Key Market Trends & Insights:

• The North America rigid endoscopes market dominated the global landscape in 2024, accounting for the largest revenue share of 40.69%. This strong market position can be attributed to the region’s well-established healthcare infrastructure, high adoption of advanced medical technologies, and the increasing prevalence of chronic diseases requiring minimally invasive diagnostic and surgical procedures. Additionally, favorable reimbursement frameworks and continuous investments in healthcare innovation have further supported market growth across North America.

• Within the region, the U.S. emerged as the dominant contributor to the rigid endoscopes market in 2024. The country’s leadership is driven by a high volume of surgical procedures, widespread availability of skilled healthcare professionals, and early adoption of technologically advanced endoscopic devices. Strong research and development activities, along with the presence of major medical device manufacturers, have also reinforced the U.S. market position.

• By product type, the rigid laparoscopes segment dominated the market, capturing the largest revenue share of 28.61% in 2024. The dominance of this segment is largely due to the extensive use of rigid laparoscopes in minimally invasive abdominal and pelvic surgeries, where they offer enhanced visualization, precision, and reduced patient recovery times compared to traditional surgical approaches.

• In terms of the angle of view, the 30° segment held the largest revenue share in 2024. This segment’s leadership can be attributed to its versatility and widespread preference among surgeons, as a 30° angle of view provides improved visualization of anatomical structures while allowing better maneuverability during complex surgical procedures.

• With respect to end use, the hospitals segment accounted for the largest revenue share in 2024. Hospitals remain the primary settings for rigid endoscope usage due to their high patient inflow, availability of advanced surgical infrastructure, and ability to perform a wide range of diagnostic and therapeutic procedures, making them the dominant end users in the rigid endoscopes market.

Order a free sample PDF of the Rigid Endoscopes Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 7.31 Billion

• 2033 Projected Market Size: USD 11.11 Billion

• CAGR (2025-2033): 4.74%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Key participants in the rigid endoscopes industry are actively focusing on the development and implementation of innovative business growth strategies to strengthen their competitive positioning in the market. These strategies include expanding and diversifying their product portfolios to address a wider range of clinical applications and evolving customer requirements.

In addition, companies are increasingly engaging in partnerships and collaborations with healthcare providers, research institutions, and technology firms to enhance product development capabilities and accelerate innovation. Market players are also pursuing mergers and acquisitions to expand their technological expertise, increase market reach, and consolidate their presence across key regions. Furthermore, efforts to broaden business footprints through geographic expansion and improved distribution networks are enabling companies to reach new markets and strengthen their global presence.

Key Players

• Olympus Corporation

• Arthrex, Inc.

• Karl Storz GmbH & Co. KG

• Stryker Corporation

• Smith+Nephew

• Richard Wolf GmbH

• Medtronic Plc

• B. Braun Melsungen AG

• CONMED Corporation

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The rigid endoscopes market is experiencing steady growth, driven by the rising demand for minimally invasive surgical and diagnostic procedures across multiple medical specialties. Increasing prevalence of chronic diseases, including cancer, along with advancements in endoscopic imaging and surgical techniques, is supporting wider adoption. Well-established healthcare infrastructure and high procedural volumes in developed regions continue to strengthen market demand, while emerging economies offer growth opportunities. Ongoing product innovation and strategic initiatives by key players are expected to further enhance market penetration and clinical outcomes.